Kraig Biocraft Laboratories (KBLB) Common Equity (2016 - 2022)
Kraig Biocraft Laboratories (KBLB) has disclosed Common Equity for 11 consecutive years, with -$3.8 million as the latest value for Q3 2022.
- Quarterly Common Equity rose 35.86% to -$3.8 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was -$3.8 million through Sep 2022, up 35.86% year-over-year, with the annual reading at -$5.3 million for FY2021, N/A changed from the prior year.
- Common Equity hit -$3.8 million in Q3 2022 for Kraig Biocraft Laboratories, roughly flat from -$3.8 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of -$3.6 million in Q1 2018 to a low of -$6.9 million in Q1 2021.
- Historically, Common Equity has averaged -$4.5 million across 4 years, with a median of -$4.1 million in 2019.
- Biggest five-year swings in Common Equity: crashed 34.53% in 2018 and later surged 40.36% in 2022.
- Year by year, Common Equity stood at -$4.5 million in 2018, then dropped by 3.28% to -$4.6 million in 2019, then fell by 14.99% to -$5.3 million in 2021, then rose by 28.51% to -$3.8 million in 2022.
- Business Quant data shows Common Equity for KBLB at -$3.8 million in Q3 2022, -$3.8 million in Q2 2022, and -$4.1 million in Q1 2022.